| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Ilan Levin | Director, 10%+ Owner | $1,830,723 | 07 Aug 2025 | ||
| Ilan Hadar | Chairman and CEO, Director | $162,081 | 20 Feb 2026 | ||
| Mitchell Shirvan | CSO and CDO | $124,891 | 20 Feb 2026 | ||
| Mirit Horenshtein Hadar | CFO and Secretary | $122,356 | 20 Feb 2026 | ||
| Avner Lushi | Director | $88,044 | 20 Feb 2026 | ||
| Shlomo Noy | Director | $88,044 | 20 Feb 2026 | ||
| Ruth Alon | Director | $51,027 | 20 Feb 2026 | ||
| Dror Yosef Abramov | Director | $50,910 | 20 Feb 2026 | ||
| Amnon Peled | Director | $41,823 | 20 Feb 2026 | ||
| Wildcat Capital Management, LLC | 10%+ Owner | 15 Aug 2024 | |||
| Ilan Shiloah | Director | 15 Aug 2024 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Shlomo Noy | SLXN | Ordinary Shares | Award | 55.8% | 9,091 | 25,399 | 20 Feb 2026 | By Guangzhou Sino-Israel Biotech Fund | ||
| Shlomo Noy | SLXN | Stock Option (right to buy ordinary shares) | Award | 10,685 | 10,685 | 20 Feb 2026 | By Guangzhou Sino-Israel Biotech Fund | |||
| Ruth Alon | SLXN | Ordinary Shares | Award | 799.6% | 9,091 | 10,228 | 20 Feb 2026 | Direct | ||
| Ruth Alon | SLXN | Stock Option (right to buy Ordinary Shares) | Award | 10,685 | 10,685 | 20 Feb 2026 | Direct | |||
| Mitchell Shirvan | SLXN | Ordinary Shares | Award | 5068.9% | 49,726 | 50,707 | 20 Feb 2026 | Direct | ||
| Mirit Horenshtein Hadar | SLXN | Ordinary Shares | Award | 11839.5% | 49,726 | 50,146 | 20 Feb 2026 | Direct | ||
| Ilan Hadar | SLXN | Ordinary Shares | Award | 5740.4% | 64,350 | 65,471 | 20 Feb 2026 | Direct | ||
| Dror Yosef Abramov | SLXN | Ordinary Shares | Award | 834.8% | 9,091 | 10,180 | 20 Feb 2026 | Direct | ||
| Dror Yosef Abramov | SLXN | Stock Option (right to buy ordinary shares) | Award | 10,685 | 10,685 | 20 Feb 2026 | Direct | |||
| Amnon Peled | SLXN | Ordinary Shares | Award | 1146.1% | 7,576 | 8,237 | 20 Feb 2026 | Direct | ||
| Amnon Peled | SLXN | Stock Option (right to buy Ordinary Shares) | Award | 8,904 | 8,904 | 20 Feb 2026 | Direct | |||
| Avner Lushi | SLXN | Ordinary Shares | Award | 55.8% | 9,091 | 25,399 | 20 Feb 2026 | By Guangzhou Sino-Israel Biotech Fund | ||
| Avner Lushi | SLXN | Stock Option (right to buy ordinary shares) | Award | 10,685 | 10,685 | 20 Feb 2026 | By Guangzhou Sino-Israel Biotech Fund | |||
| Ilan Levin | SLXN | Ordinary Shares | Award | 6456.2% | 450,000 | 456,970 | 15 Sep 2025 | By Moringa Sponsor, LP. | ||
| Ilan Levin | SLXN | Ordinary Shares | Other | -44.3% | -5,550 | 6,970 | 07 Aug 2025 | By Moringa Sponsor, LP. | ||
| Ilan Levin | SLXN | Warrant (right to buy) | Other | -71.5% | -935 | 372 | 07 Aug 2025 | By Moringa Sponsor, LP. |